This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
Presentation of the early ARISE results at the 2019 Meeting of the European Association for Cardio-Thoracic-Surgery (EACTS) Saturday 5th of October in Lisbon, Portugal
Results for pediatric aortic valve replacement using cell-free homografts will be presented as well at the EACTS 2019 [more]
Early results of the ESPOIR Trial now published
The early results of the ESPOIR Trial and the ESPOIR Registry, including a matched comparison to conventional cryopreserved homografts and bovine jugular vein conduits (Contegra®) now have been published and are available here. [more]
Patient lecture and seminar on regenerative heart valves and stem cell therapy options - 30.03.2019 in the Hannover Zoo
Patientenseminar: Regenerative Therapien und Stammzelltherapie bei angeborenen Herzfehlern – geht das schon? [more]
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.